Figure 6: In vivo treatment of Q2-3 confers comparable anti-metastatic activity with IL-25 administration.
From: Induction of IL-25 secretion from tumour-associated fibroblasts suppresses mammary tumour metastasis
(a) Tumour-resected mice (n=8 per group) were treated with PBS (0.1% DMSO in saline), IL-25 (200 ng per mice), Q2-3 (100 μg kg−1) or co-treated with IL-25 and Q2-3 for 3 weeks. Quantification of tumour metastasis by measuring luciferase activity in photons s−1 cm−2 sr−1 in mice revealed along the indicated time course. (b) Survival of test mice after different treatments. NS, no significant difference between the Q2-3 and co-treatment groups (Kaplan–Meier results were analysed by log-rank test). Similar results were obtained from three independent experiments.
